Clinical trials: Dose Finding Study
Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent
A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors.
- Conditions
- Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma
- Trial name
- PROFILE 1001 (NCT00585195)
- Testing
- PF-02341066, Rifampin, Itraconazole
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 596 people
- Sponsor
- Pfizer
Prostate Cancer
A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer
A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer,Assigned to Active Surveillance who…
- Trial name
- NCT03348527
- Testing
- 2-Hydroxyflutamide Depot
- Where
- 10 sites in Canada, Finland and 1 more
- Volunteers
- 61 people
- Sponsor
- Lidds AB
Ulcerative Colitis
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy with an option for open-label treatment…
- Trial name
- CALDOSE-1 (NCT03341962)
- Testing
- IMU-838
- Where
- 131 sites in United States, Albania and 17 more
- Volunteers
- 263 people
- Sponsor
- Immunic AG
Chronic Kidney Disease
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria.
- Trial name
- MIRO-CKD (NCT06350123)
- Where
- 92 sites in United States, Austria and 13 more
- Volunteers
- 324 people
- Sponsor
- AstraZeneca
Cancer of the Prostate
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
The objective of this clinical study is to evaluate the safety and efficacy of three different doses of BHR-200 (0.36% transdermal estradiol gel) compared to placebo for the maintenance of testosterone (T) suppression in men with…
- Trial name
- MASTERS (NCT02349386)
- Testing
- BHR-200 (0.36% transdermal 17β-estradiol gel)
- Where
- 12 sites in United States
- Volunteers
- 34 people
- Sponsor
- BHR Pharma, LLC
Advanced Malignancies
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or novel anti-cancer agents in participants with…
- Trial name
- NCT03907969
- Testing
- AZD7648, PLD
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Anemia in Pre-Dialysis Patients
Phase II Dose-Finding of Oral SSS17 for Anemia in Non-Dialysis CKD
This study primarily evaluates the efficacy and safety of oral SSS17 capsules in treating anemia in patients with non-dialysis chronic kidney disease, as well as the pharmacokinetic and pharmacodynamic (PK/PD) characteristics of…
- Trial name
- NCT07014631
- Testing
- SSS17
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Enterovirus Infections
A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects
The objectives of this study are to evaluate the immune response and safety profiles of two injections of EV71 vaccine administrated with or without adjuvant Al(OH)3 at 0.5-μg and 1-μg dose in children aged 3 to 6 years old and 2…
- Trial name
- NCT03268083
- Testing
- EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose), EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose), EV71 vaccine ([1 μg total protein ] per dose)
- Where
- 4 sites in Taiwan
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Enimmune Corporation
Healthy
Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
The study is carried out in order to determine the relationship between AZD2066 exposure and mGluR5 receptor occupancy in the brain and to demonstrate that AZD2066 can displace [11C]AZ12713580 from mGluR5 binding-sites in the…
- Trial name
- PET (NCT00686504)
- Testing
- AZD2066, radioligand [11C] AZ12713580
- Where
- Sweden
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes.
- Trial name
- NCT05144984
- Testing
- NNC0480-0389, Semaglutide
- Where
- 129 sites in United States, Bulgaria and 7 more
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Pancreatic Carcinoma Stage II, Cholangiocarcinoma Resectable
Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
This is a phase I/II study which intends to characterize the safety, tolerability, and preliminary efficacy of Allogeneic Magicell-NK infusion in PDA or cholangiocarcinoma patients after surgery.
- Trial name
- NCT06730009
- Testing
- SLOG + Allogeneic NK cell, SLOG chemotherapy
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Medigen Biotechnology Corporation
sFlt1 Mediated Preterm Preeclampsia, Preeclampsia
A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months
This study is a dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CBP-4888 in hospitalized participants with Preterm Preeclampsia receiving Standard of Care, Expectant…
- Conditions
- sFlt1 Mediated Preterm Preeclampsia, Preeclampsia, Preterm Preeclampsia
- Trial name
- NCT07282171
- Testing
- CBP-4888
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Comanche Biopharma
Chronic Abacterial Prostatitis, Chronic Pelvic Pain Syndrome
A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
In this study several doses of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of patients with Chronic abacterial Prostatitis / Chronic Pelvic Pain Syndrome.
- Trial name
- AZURE (NCT01391338)
- Testing
- ASP3652
- Where
- 49 sites in Czechia, Germany and 4 more
- Volunteers
- 239 people
- Sponsor
- Astellas Pharma Inc
Neoplasms
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
This is a dose-finding study; therefore, there is no hypothesis testing
- Trial name
- NCT00607048
- Testing
- Paclitaxel + Carboplatin + CP-870,893
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Cancer, Malignancy
A Study of ASN007 in Patients With Advanced Solid Tumors
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups.
- Conditions
- Cancer, Malignancy, Neoplasia, Neoplasm
- Trial name
- NCT03415126
- Testing
- ASN007: ascending doses, ASN007 RD
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Asana BioSciences
Prostate Cancer
Phase II, Dose Finding Study of GTx-758
The purpose of this study is to determine the appropriate loading and maintenance dose of GTx-758 to reach and maintain castration for the duration of the study.
- Trial name
- NCT01393119
- Testing
- GTx-758
- Where
- 21 sites in United States
- Volunteers
- 77 people
- Sponsor
- GTx
Heart Failure, Congestive, Edema
A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
This drug is being developed to treat cardiac edema. The primary purpose of this study is to investigate the dose response for body weight in seven-day repeated oral administration of OPC-41061 at 15, 30, and 45 mg or placebo in…
- Trial name
- NCT00234104
- Testing
- OPC-41061(Tolvaptan)
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Glioblastoma
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
- Trial name
- NCT05109728
- Testing
- [177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine will be investigated in healthy children aged 6 to 16 years.
- Trial name
- NCT00161798
- Testing
- Tick-borne encephalitis vaccine
- Where
- 23 sites in Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Osteoarthritis, Knee
A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS
The purpose of this study is to determine whether intra-articular (knee joint) administration of MEN16132 is effective reducing the pain from knee osteoarthritis.
- Trial name
- ALBATROSS (NCT01091116)
- Testing
- MEN16132 - 0.125 mg, MEN16132 - 0.25 mg, MEN16132 - 0.5 mg
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 423 people
- Sponsor
- Menarini Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.